Why is mucormycosis more difficult to cure than more common mycoses?

Clinical Microbiology and Infection

Volumn 20, Issue 6, 2014, Pages 74-81

  Katragkou, A ^a,b   Walsh, T J ^b   Roilides, E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Aspergillus fumigatus; Mucormycosis; Rhizopus oryzae; Zygomycosis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CHELATING AGENT; SIDEROPHORE;

ANTIBIOTIC SENSITIVITY; BLOOD VESSEL; DEBRIDEMENT; DRUG USE; EARLY DIAGNOSIS; FUNGUS; FUNGUS CULTURE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MORTALITY; MOULD; MUCORMYCOSIS; MYCOSIS; PRIORITY JOURNAL; REVIEW; RHIZOPUS ORYZAE; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; THERAPY DELAY; VIRULENCE; ZYGOMYCOSIS; IMMUNOLOGY; MYCOSES; RISK;

ANTIFUNGAL AGENTS; HUMANS; MUCORMYCOSIS; MYCOSES; RISK;

EID: 84922274476     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12466     Document Type: Review

References (69)

1. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 (suppl 1): 48-66.
2. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-1867.
3. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
4. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-rhizopus, -mucor, and -lichtheimia species. Clin Microbiol Rev 2011; 24: 411-445.
5. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
6. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-569.
7. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
8. Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: e1286-e1294.
9. Steinbach WJ, Marr KA, Anaissie EJ et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the path alliance registry. J Infect 2012; 65: 453-464.
10. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-1751.
11. Ruping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296-302.
12. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2009; 15 (suppl 5): 50-54.
13. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK Jr, Walsh TJ. Zygomycosis in neonates: an uncommon but life-threatening infection. Am J Perinatol 2009; 26: 565-573.
14. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in france: the retrozygo study (2005-2007). Clin Infect Dis 2012; 54 (suppl 1): S35-S43.
15. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (suppl 1): S23-S34.
16. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (suppl 1): 31-47.
17. Chakrabarti A, Das A, Mandal J et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006; 44: 335-342.
18. Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-727.
19. Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infect 2006; 12: 404-409.
20. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 2012; 54 (suppl 1): S61-S66.
21. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54 (suppl 1): S16-S22.
22. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008; 52: 722-724.
23. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997; 175: 1012-1015.
24. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon gamma and granulocyte-macrophage colonystimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191: 1180-1187.
25. Simitsopoulou M, Georgiadou E, Walsh TJ, Roilides E. Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. Med Mycol 2010; 48: 720-724.
26. Petraitis V, Petraitiene R, Antachopoulos C et al. Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. Med Mycol 2013; 51: 72-82.
27. Chamilos G, Lewis RE, Hu J et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008; 105: 9367-9372.
28. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002; 16: 895-914, vi.
29. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-856.
30. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
31. Warris A, Netea MG, Verweij PE et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. Med Mycol 2005; 43: 613-621.
32. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 2009; 59: 134-138.
33. Ma LJ, Ibrahim AS, Skory C et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5: e1000549.
34. Boelaert JR, van Roost GF, Vergauwe PL, Verbanck JJ, de Vroey C, Segaert MF. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 1988; 29: 261-266.
35. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979-1986.
36. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994; 45: 667-671.
37. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994; 47: 1843-1850.
38. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989; 36: 1061-1068.
39. Lewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, Kontoyiannis DP. Activity of deferasirox in mucorales: influences of species and exogenous iron. Antimicrob Agents Chemother 2011; 55: 411-413.
40. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129: 569-582.
41. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150: 752-760.
42. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199: 1399-1406.
43. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54 (suppl 1): S55-S60.
44. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214.
45. Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis: report of four cases and review. Rev Infect Dis 1989; 11: 741-754.
46. Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med 1984; 108: 616-618.
47. Dannaoui E. Molecular tools for identification of zygomycetes and the diagnosis of zygomycosis. Clin Microbiol Infect 2009; 15 (suppl 5): 66-70.
48. Kasai M, Harrington SM, Francesconi A et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 2008; 46: 3690-3702.
49. Schwarz P, Bretagne S, Gantier JC et al. Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol 2006; 44: 340-349.
50. Machouart M, Larche J, Burton K et al. Genetic identification of the main opportunistic mucorales by pcr-restriction fragment length polymorphism. J Clin Microbiol 2006; 44: 805-810.
51. Iwen PC, Freifeld AG, Sigler L, Tarantolo SR. Molecular identification of Rhizomucor pusillus as a cause of sinus-orbital zygomycosis in a patient with acute myelogenous leukemia. J Clin Microbiol 2005; 43: 5819-5821.
52. Lechevalier P, Hermoso DG, Carol A et al. Molecular diagnosis of Saksenaea vasiformis cutaneous infection after scorpion sting in an immunocompetent adolescent. J Clin Microbiol 2008; 46: 3169-3172.
53. Kobayashi M, Togitani K, Machida H, Uemura Y, Ohtsuki Y, Taguchi H. Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by Cunninghamella bertholletiae. Respirology 2004; 9: 397-401.
54. Larche J, Machouart M, Burton K et al. Diagnosis of cutaneous mucormycosis due to Rhizopus microsporus by an innovative PCR-restriction fragment-length polymorphism method. Clin Infect Dis 2005; 41: 1362-1365.
55. Dannaoui E, Schwarz P, Slany M et al. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative european society of clinical microbiology and infectious diseases (escmid) fungal infection study group (efisg) evaluation. J Clin Microbiol 2010; 48: 2043-2046.
56. Balajee SA, Sigler L, Brandt ME. DNA and the classical way: identification of medically important molds in the 21st century. Med Mycol 2007; 45: 475-490.
57. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52: 1144-1155.
58. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015.
59. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin b, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582.
60. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
61. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
62. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002-1011.
63. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis 2012; 54 (suppl 1): S67-S72.
64. Ibrahim AS, Gebremariam T, Husseiny MI et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008; 52: 1573-1576.
65. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51: 1253-1258.
66. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010; 54: 1298-1304.
67. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin b-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-509.
68. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-727.
69. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 2008; 4: e1000040.